AVXL Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
6.8M
-37.5%
10.8M
-25.0%
14.5M
+15.6%
12.5M
-7.9%
13.6M
R&D
4.7M
-36.2%
7.3M
-26.8%
10.0M
+0.7%
9.9M
-5.3%
10.4M
SG&A
2.1M
-40.1%
3.5M
-21.1%
4.5M
+71.7%
2.6M
-16.7%
3.1M
Operating Income
-6782000
+37.5%
-10844000
+25.0%
-14459000
-15.6%
-12513000
+7.9%
-13592000
EBITDA
-6782000
+37.5%
-10844000
+25.0%
-14459000
-15.6%
-12513000
+7.9%
-13592000
Net Income
-5681000
+42.2%
-9827000
+25.8%
-13243000
-18.3%
-11196000
+7.6%
-12111000
EPS (Basic)
$-0.06
+45.5%
$-0.11
+31.3%
$-0.16
-23.1%
$-0.13
+7.1%
$-0.14
EPS (Diluted)
$-0.06
+45.5%
$-0.11
+31.3%
$-0.16
-23.1%
$-0.13
+7.1%
$-0.14
Shares (Diluted)
89.0M
+3.6%
85.9M
+0.6%
85.4M
+0.4%
85.1M
+0.3%
84.8M
Anavex Life Sciences (AVXL) โ€” Financials